Home > Healthcare > Medical Devices > Diagnostic Devices > chlamydia infection diagnostics market
Get a free sample of Chlamydia Infection Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Chlamydia Infection Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The market features a diverse range of companies. Leading corporations are focused on strengthening their market position through new product releases, mergers and acquisitions, and the adoption of cutting-edge technologies.
Some of the eminent market participants operating in the chlamydia infection diagnostics industry include:
The chlamydia infection diagnostics industry was valued at USD 1.5 billion in 2023 and is likely to record a 7.1% CAGR through 2032, propelled by technological advancements, increased awareness, and evolving healthcare needs.
The nucleic acid amplification test (NAAT) segment in the market attained USD 668.3 million in 2023 due to their high sensitivity and specificity.
North American chlamydia infection diagnostics market accounted for USD 588.1 million in 2023, amplifying the demand for effective diagnostic solutions to manage and control the spread of the infection.
Abbott, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, and Hologic, Inc., among others.